Posted on 25/11/2009 in Pharmaceutical Company Product News Chugai has announced the launch of its latest corporate advertisement, which aims to inform its audience about the company's current mission statement.
This, the firm highlights, is to develop and market innovative treatments by utilising state-of-the-art technologies and therefore position itself as a major biopharmaceutical and antibody pharmaceuticals provider.
Its corporate advertisement was last altered in 2005.
Entitled Innovative Ideas Begin Here, the piece aims to highlight the firm's contributions to treatments for diseases such as cancer, renal anaemia, hepatitis C and rheumatoid arthritis.
In particular, Chugai wishes to focus on treatments for medical needs that are currently unmet.
Meanwhile, last week, the company announced alongside Roche that the drug they developed in cooperation - RoACTEMRA, (tocilizumab) - yielded a successful outcome in a recent study.
The product met its primary endpoint in a paediatric study of systemic onset Juvenile Idiopathic Arthritis, by noticeably reducing the symptoms of the disease.
Other news stories from 25/11/2009
Read more in the Zenopa News Archive
How this news is generated
|
